Genentech Receives FDA Approval for Cancer Treatment
By Connor Hart
Genentech has received Food and Drug Administration approval for its treatment of certain types of lung, liver, skin and soft tissue cancer in adults.
The treatment, called Tecentriq Hybreza, can be injected under the skin through an injection over approximately seven minutes, compared with between 30 minutes and 60 minutes for a standard IV-infusion of Tecentriq, according to Genentech, a member of the Roche Group.
Tecentriq Hybreza combines Tecentriq, used to treat tumor cells and tumor-infiltrating immune cells with a drug-delivery technology that increases the permeability of the tissue under the skin, the company said Thursday.
The FDA approval is based on data from Genentech's Phase IB/III IMscin001 study, according to the company, which showed comparable levels of Tecentriq in the blood, "when administered subcutaneously, and a safety and efficacy profile consistent with the IV formulation."
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
September 12, 2024 20:16 ET (00:16 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
3 Dividend Stocks for October 2024
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued